Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...

Sequential BCL2 inhibitor therapy shows initial responses but lacks durability, especially in patients exposed to both BTKi ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Extended ibrutinib and venetoclax therapy improves outcomes in R/R CLL, with a 40% complete response rate and high survival rates. A six-month ibrutinib lead-in reduces tumor burden and tumor lysis ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...